GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Endoscopy/EUS-FNAB for Solid Pancreatic Lesions: GIE | July 2026

EUS-FNAB for Solid Pancreatic Lesions: GIE | July 2026

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated July 1, 2026

Quick Answer

Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support.


Introduction:

Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing FNB tissue in formalin for histopathology could provide comparable diagnostic performance.

Why was this study needed?

  • Many centers lack rapid on-site cytopathology (ROSE) or dedicated cytopathologists.
  • Histopathology may better preserve tissue architecture for diagnosis and ancillary testing.
  • The optimal processing method for EUS-FNB specimens remains uncertain.
  • Simplifying specimen handling could improve workflow and reduce procedure time.
  • Prospective data comparing histopathology with conventional cytology are limited.

Results:

  • Histopathologic evaluation of EUS-FNB specimens achieved diagnostic accuracy comparable to conventional cytology for solid pancreatic lesions.
  • Histopathology required fewer needle passes, potentially reducing procedure time and improving efficiency.
  • With macroscopic on-site evaluation (MOSE), all histopathology specimens were adequate for analysis, supporting its reliability even without on-site cytopathologists.

Clinical Impact:

This study supports direct formalin submission of EUS-FNB specimens for histopathology as a practical alternative to cytology, particularly in centers without ROSE or cytopathology services. It may simplify specimen processing while maintaining excellent diagnostic performance.

Bottom Line:

Histopathology with MOSE is a reliable alternative to cytology for EUS-FNB of solid pancreatic lesions. It provides comparable diagnostic accuracy with fewer needle passes, making it an attractive approach for routine clinical practice, especially in resource-limited settings.

Related Q&A

EndoBarrier Improves Diabetes and Weight Loss: Ann Surg | July 2026

Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...

Immediate Endoscopic Necrosectomy in Necrotizing Pancreatitis: Gastroenterology | July 2026

Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...

Endoscopy After Bevacizumab Appears Safe: GIE | July 2026

Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...

Colorectal ESD Perforation: Endoscopy | July 2026

Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...

Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...

Durable Endoscopic Partial Reversal of Roux-en-Y Gastric Bypass Using Parallel LAMS Septotomy: GIE | July 2026

Introduction: Although Roux-en-Y gastric bypass (RYGB) is an effective bariatric procedure, a small proportion of patients develop severe nutritional complications, refractory dumping syndrome, or other debilitating adverse events requiring reversal. This study describes a novel...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer